SG11202005296SA - Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer - Google Patents
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancerInfo
- Publication number
- SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA SG 11202005296S A SG11202005296S A SG 11202005296SA
- Authority
- SG
- Singapore
- Prior art keywords
- immunotherapy
- combination therapy
- treat cancer
- progastrin antibody
- progastrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594755P | 2017-12-05 | 2017-12-05 | |
| PCT/EP2018/083651 WO2019110662A1 (en) | 2017-12-05 | 2018-12-05 | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005296SA true SG11202005296SA (en) | 2020-07-29 |
Family
ID=64949216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005296SA SG11202005296SA (en) | 2017-12-05 | 2018-12-05 | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11046758B2 (zh) |
| EP (1) | EP3720879B1 (zh) |
| JP (1) | JP7104153B2 (zh) |
| KR (1) | KR102461238B1 (zh) |
| CN (1) | CN111670197A (zh) |
| AU (1) | AU2018379320B2 (zh) |
| CA (1) | CA3084687C (zh) |
| DK (1) | DK3720879T3 (zh) |
| ES (1) | ES2920283T3 (zh) |
| PL (1) | PL3720879T3 (zh) |
| PT (1) | PT3720879T (zh) |
| SG (1) | SG11202005296SA (zh) |
| TW (1) | TWI763956B (zh) |
| WO (1) | WO2019110662A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3720879T (pt) * | 2017-12-05 | 2022-07-13 | Progastrine Et Cancers S A R L | Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro |
| EP3759492A1 (en) * | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
| CN111171146B (zh) * | 2020-02-20 | 2022-03-04 | 西北农林科技大学 | 抗h9n2亚型禽流感病毒的纳米抗体、制备方法和应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5546806A (en) | 1991-10-17 | 1996-08-20 | Kain; Aron Z. | Microwave vector displacement and acceleration transducer |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5474896A (en) | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| ATE387495T1 (de) | 1996-12-03 | 2008-03-15 | Amgen Fremont Inc | Vollkommen humane antikörper die egfr binden |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| TR199902553T2 (xx) | 1997-04-14 | 2000-03-21 | Micromet Gesellschaft F�R Biomedizinische Forschung Mbh | �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�. |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| DE60236182D1 (de) | 2001-09-14 | 2010-06-10 | Cellectis | Zufällige integration von polynukleotide nach in vivo linearisierung |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| JP2006518372A (ja) | 2003-01-28 | 2006-08-10 | セレクティス | 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用 |
| JP2008513536A (ja) | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| CA2703045C (en) | 2007-10-25 | 2017-02-14 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
| LT2488551T (lt) * | 2009-10-16 | 2018-10-25 | Progastrine Et Cancers S.A R.L. | Monokloniniai antikūnai prieš progastriną ir jų panaudojimas |
| US9217032B2 (en) * | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| US9487582B2 (en) * | 2010-01-08 | 2016-11-08 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for treating pancreatic cancer |
| JP5829672B2 (ja) * | 2010-03-24 | 2015-12-09 | レ ラボラトワール セルヴィエ | 結腸直腸及び胃腸癌の予防 |
| BR112013002012A2 (pt) * | 2010-07-26 | 2019-08-27 | Centre Nat Rech Scient | métodos e composições para terapia de câncer de fígado |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| AU2015339306B2 (en) * | 2014-10-29 | 2021-07-22 | Bristol-Myers Squibb Company | Combination therapy for cancer |
| KR102430893B1 (ko) * | 2015-12-31 | 2022-08-09 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 식도암을 검출 및 치료하기 위한 조성물 및 방법 |
| AU2017204682B2 (en) * | 2015-12-31 | 2021-07-29 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| WO2017114975A1 (en) * | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating gastric cancer |
| EP3602061B1 (en) * | 2017-03-30 | 2022-07-20 | ECS-Progastrin SA | Compositions and methods for detecting lung cancer |
| CA3058263C (en) * | 2017-03-30 | 2023-08-01 | Ecs-Progastrin Sa | Compositions and methods for detecting prostate cancer |
| CA3066756A1 (en) * | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
| PT3720879T (pt) * | 2017-12-05 | 2022-07-13 | Progastrine Et Cancers S A R L | Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro |
| EP3759492A1 (en) * | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrin as a biomarker for immunotherapy |
-
2018
- 2018-12-05 PT PT188297428T patent/PT3720879T/pt unknown
- 2018-12-05 SG SG11202005296SA patent/SG11202005296SA/en unknown
- 2018-12-05 US US16/769,844 patent/US11046758B2/en active Active
- 2018-12-05 TW TW107143746A patent/TWI763956B/zh active
- 2018-12-05 PL PL18829742.8T patent/PL3720879T3/pl unknown
- 2018-12-05 DK DK18829742.8T patent/DK3720879T3/da active
- 2018-12-05 WO PCT/EP2018/083651 patent/WO2019110662A1/en active Application Filing
- 2018-12-05 CN CN201880088139.2A patent/CN111670197A/zh active Pending
- 2018-12-05 ES ES18829742T patent/ES2920283T3/es active Active
- 2018-12-05 AU AU2018379320A patent/AU2018379320B2/en active Active
- 2018-12-05 CA CA3084687A patent/CA3084687C/en active Active
- 2018-12-05 JP JP2020530573A patent/JP7104153B2/ja active Active
- 2018-12-05 KR KR1020207019218A patent/KR102461238B1/ko active IP Right Grant
- 2018-12-05 EP EP18829742.8A patent/EP3720879B1/en active Active
-
2021
- 2021-06-25 US US17/358,480 patent/US20210324069A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111670197A (zh) | 2020-09-15 |
| US11046758B2 (en) | 2021-06-29 |
| EP3720879B1 (en) | 2022-05-11 |
| RU2020121176A (ru) | 2022-01-10 |
| JP7104153B2 (ja) | 2022-07-20 |
| KR102461238B1 (ko) | 2022-11-01 |
| US20210009680A1 (en) | 2021-01-14 |
| AU2018379320B2 (en) | 2023-06-15 |
| CA3084687C (en) | 2024-01-02 |
| RU2020121176A3 (zh) | 2022-04-27 |
| KR20200118409A (ko) | 2020-10-15 |
| ES2920283T3 (es) | 2022-08-02 |
| WO2019110662A1 (en) | 2019-06-13 |
| PT3720879T (pt) | 2022-07-13 |
| EP3720879A1 (en) | 2020-10-14 |
| TW201927805A (zh) | 2019-07-16 |
| PL3720879T3 (pl) | 2022-09-12 |
| CA3084687A1 (en) | 2019-06-13 |
| DK3720879T3 (da) | 2022-06-20 |
| JP2021505576A (ja) | 2021-02-18 |
| TWI763956B (zh) | 2022-05-11 |
| AU2018379320A1 (en) | 2020-07-02 |
| US20210324069A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| IL262562A (en) | Combination of anti-pd-1 antibodies and radiation for cancer therapy | |
| IL268138A (en) | Combinations of cabozantinib and atezolizumab for cancer treatment | |
| IL247066A0 (en) | Cancer immunotherapy by combining local and systemic immune stimulation | |
| HK1247630A1 (zh) | 用於增强癌症治療的效果的組合物和方法 | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| HRP20190888T8 (hr) | Konjugat antitijela za igf-1r i lijeka i njegova upotreba u liječenju karcinoma | |
| IL248704A0 (en) | Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2 | |
| IL275517A (en) | Combined methods and treatment of cancer | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| SG11201707949XA (en) | Anti-vegfr2 human antibody for anti-angiogenic and targeted cancer therapy | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| FI3630112T3 (fi) | Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa | |
| IL275913A (en) | Methods and combined treatment for cancer treatment | |
| IL274866A (en) | Preparations and methods for the treatment of cancer | |
| GB201717004D0 (en) | Methods of cancer therapy | |
| GB201711769D0 (en) | Methods of cancer therapy | |
| GB201416605D0 (en) | Combination therapy to reduce the risk of and to treat cancer |